5 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 2.9% per year over the past 4 years.
Net income has grown faster than revenue (10.7% vs 2.9% per year).
Operating margin has expanded, at 10.7% in the latest year.
Free cash flow has grown 2.9% per year over the past 4 years.
Financial health
Total debt ($113M) exceeds cash ($23M); net debt is $90M.
Total debt has grown slower than revenue (-13.6% vs 2.9% per year).
Operating income covered interest expense 5.3× in the latest year, up from 4.9× 4 years ago.
Total debt is 1.6× EBITDA.
Shareholder returns
Dividends have been paid for 5 consecutive years, consuming 6.3% of earnings and 7.2% of free cash flow.
The dividend has grown 0.5% per year over the past 4 years.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$527M
$30M
20.7%
10.7%
$26M
$113M
$23M
2024
$524M
$31M
19.7%
11.2%
$45M
$128M
$19M
2023
$510M
$37M
21.5%
10.7%
$14M
$166M
$15M
2022
$490M
$19M
19.6%
8.5%
$15M
$175M
$15M
2021
$470M
$20M
0.0%
9.6%
$23M
—
—
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$122M
-$789000
16.2%
1.5%
$517000
$117M
$23M
Dec '25
$138M
$5M
20.8%
11.5%
$5M
$113M
$23M
Sep '25
$135M
$14M
22.0%
15.6%
$6M
$117M
$26M
Jun '25
$130M
$11M
20.3%
11.7%
$10M
$126M
$31M
Mar '25
$124M
-$154000
19.5%
3.6%
$4M
$126M
$22M
Dec '24
$129M
$7M
17.8%
11.0%
$17M
$128M
$19M
Sep '24
$134M
$12M
20.5%
14.7%
$10M
$142M
$21M
Jun '24
$131M
$9M
21.2%
12.3%
$14M
$150M
$18M
Mar '24
$130M
$3M
19.3%
6.6%
$2M
$163M
$15M
Dec '23
$128M
$2M
0.0%
11.4%
$17M
$166M
$15M
Sep '23
$125M
$9M
0.0%
11.7%
-$4M
$181M
$17M
Jun '23
$128M
$23M
0.0%
14.8%
$7M
$185M
$26M
Mar '23
$128M
$2M
0.0%
5.0%
-$5M
—
—
Dec '22
$128M
$7M
0.0%
12.2%
$11M
$175M
$15M
Sep '22
$126M
$8M
0.0%
11.6%
$3M
—
—
Jun '22
$121M
$7M
0.0%
9.6%
—
—
—
Valuation over time
How the market has priced CLB against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 52.3× (Mar '23) to 17.0× (Jun '26).
The price-to-sales ratio has fallen from 2.1× (Mar '23) to 1.0× (Jun '26).
The dividend yield has risen from 0.2% (Mar '23) to 0.4% (Jun '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Dividend yield (%)
Dividend yield %
Frequently asked questions
Is CLB growing its revenue and profit?
Over the past 4 years, Core Laboratories Inc. /De/'s revenue has grown 2.9% per year, and net income grown 10.7% per year. These are computed facts, not advice.
How much debt does CLB have?
As of FY2025, Core Laboratories Inc. /De/ reported $113M of total debt against $23M of cash; operating income covered interest expense 5.3×.
What is CLB's profit margin?
In FY2025, gross margin was 20.7%, operating margin 10.7%, and net margin 5.6%.
What is CLB's P/E ratio?
As of Jun '26, Core Laboratories Inc. /De/ traded at a price-to-earnings ratio of about 17.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.